NCT00619996View on ClinicalTrials.gov

Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2009

Conditions
Prostate Cancer
Interventions
DRUG

Sorafenib (Nexavar)

"Sorafenib 400 mg bid orally continuously~Sorafenib will be administered from the start of treatment in combination with Docetaxel until progression of disease."

DRUG

Docetaxel

Docetaxel 75 mg/mq ev g1 every 21 days. Docetaxel will be administered for a maximum of 9 cycles.

Trial Locations (1)

56100

Dipartimento di Oncologia, dei Trapianti e delle Nuove Tecnologie in Medicina ... Indirizzo: via Roma, 55 - 56100 Pisa Tel. 050-2218690 - Fax. 050-2218685, Pisa

All Listed Sponsors
lead

Italian Trial in Medical Oncology

OTHER

NCT00619996 - Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter